ISA MIRZA

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

Increasing U.S. support for civil society demining projects in international post-conflict zones.

-Increasing U.S. support for civil society demining projects in international post-conflict zones.

-Increasing U.S. support for civil society demining projects in international post-conflict zones.

-Increasing U.S. support for civil society demining projects in international post-conflict zones.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in conflict zones. Advocacy to increase support from State Department' Office of Weapons Removal and Abatement for such demining efforts.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in conflict zones. Advocacy to increase support from State Department' Office of Weapons Removal and Abatement for such demining efforts.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in conflict zones. Advocacy to increase support from State Department' Office of Weapons Removal and Abatement for such demining efforts.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in confict zones. Advocacy to increase support from State Department's Office of Weapons Removal and Abatement for such demining efforts.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in confict zones. Advocacy to increase support from State Department's Office of Weapons Removal and Abatement for such demining efforts.

Advocacy to increase congressional support and appropriations for APOPO's demining efforts in confict zones. Advocacy to increase support from State Department's Office of Weapons Removal and Abatement for such demining efforts.

-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)

-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)

-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)

-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)

-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)

-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)

-Regulation of molecular diagnostics. -Implementation of 21st Century Cures (P.L. 114-255).

-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).

-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).

-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).

-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).

-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).

-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).

-Medicare payment and coding for clinical laboratory tests. -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).

Medicare payment and coding for clinical laboratory tests. Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93).

Regulation of molecular diagnostics. H.R. 6 - 21st Century Cures Act (P.L. 114-255).

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.

Representation of client regarding implementation of section 603 of Public Law 114-74.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Centure Cures Initiative.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Representation of client regarding implementation of section 603 of Public Law 114-74.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Centure Cures Initiative.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Centure Cures Initiative.

Medicare payment and coding for clinical laboratory tests; H.R. 4302: Protecting Access to Medicare Act of 2014, P.L. 113-93.

Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Centure Cures Initiative.

Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act(FDASIA) Pub.L. 112-144) H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act House Committee on Energy & Commerce 21st Century Cures initiative.

Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act(FDASIA) Pub.L. 112-144) H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act House Committee on Energy & Commerce 21st Century Cures initiative.

Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the coverage and reimbursement of novel therapeutics for the treatment of obesity.

Implementation of Orphan Drug Act and orphan drug development.

Implementation of the Affordable Care Act of 2010 (Pub. L. 111-148) Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) Pub.L. 112-144) H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act

Implementation of Orphan Drug Act and orphan drug development.

Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the coverage and reimbursement of novel therapeutics for the treatment of obesity.

Implementation of Orphan Drug Act and orphan drug development.

Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the coverage and reimbursement of novel therapeutics for the treatment of obesity.

Implementation of Orphan Drug Act and orphan drug development.

Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the coverage and reimbursement of novel therapeutics for the treatment of obesity.

Implementation of Orphan Drug Act and orphan drug development.

Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the coverage and reimbursement of novel therapeutics for the treatment of obesity.

Implementation of Orphan Drug Act and orphan drug development.

Implementation of Orphan Drug Act and orphan drug development.

Patient Protection and Affordable Care Act (P.L. 111-148); Health Care and Education Reconciliation Act (P.L. 111-152) Medicare Orthotics and Prosthetics Improvement Act (H.R.1958); Insurance Fairness for Amputees Act (S. 773).